Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 11/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301221 | 0.98 | DRD2 (0.55) | MEN1KMT2ADRD2CACNA1HHSD17B10 | |
| SCHEMBL22783648 | 0.94 | DRD2 (0.52) | MEN1KMT2ADRD2CACNA1HHSD17B10 | |
| SCHEMBL31301279 | 0.92 | DRD2 (0.50) | MEN1KMT2ADRD2CACNA1HHSD17B10 | |
| SCHEMBL16941149 | 0.91 | MEN1 (0.47) | MEN1KMT2ADRD2CACNA1HHSD17B10 | |
| SCHEMBL14873885 | 0.91 | DRD2 (0.55) | MEN1KMT2ADRD2CACNA1HSIGMAR1 | |
| SCHEMBL829612 | 0.90 | DRD2 (0.56) | MEN1KMT2ADRD2SIGMAR1TDP1 | |
| SCHEMBL30433108 | 0.89 | DRD2 (0.50) | MEN1KMT2ADRD2CACNA1HHSD17B10 | |
| SCHEMBL31301242 | 0.89 | DRD2 (0.63) | MEN1KMT2ADRD2CACNA1HSIGMAR1 | |
| SCHEMBL24913972 | 0.88 | DRD2 (0.57) | MEN1KMT2ADRD2SIGMAR1TDP1 | |
| SCHEMBL22783652 | 0.88 | DRD2 (0.56) | MEN1KMT2ADRD2CACNA1HSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-119019389-B | 7-Azaindole compound and synthetic method and application thereof | SICHUAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4737898-A2 | SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE | EMP Biotech GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4304842-B1 | METHOD FOR MAKING PHOTOFUNCTIONAL CONTACT LENSES | ALCON INC (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-121574171-A | Difunctional protein degradation agent of direct targeting proteasome, preparation method and application thereof | 浙大城市学院 | 2026-02-27 | — | — | CN | disclosed |
| EP-1449844-A1 | benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
| US-5561140-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0468400-B1 | DC-89 derivatives as antitumoral agents | KYOWA HAKKO KOGYO KK (JP) | 1996-08-14 | — | — | EP | disclosed |
| US-5530119-A | IMMUNOSUPPRESSANTS | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0690713-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021254-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
| US-5332740-A | Antitumor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-07-26 | — | — | US | disclosed |
| EP-0468400-A1 | DC-89 derivatives as antitumoral agents | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | MEN1 2783/4885KMT2A 2695/4885DRD2 2023/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | MEN1 4863/4885KMT2A 29/4885DRD2 1145/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | MEN1 1998/4885KMT2A 1480/4885DRD2 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.